Aquestive Therapeutics, Inc.
Anaphylm
severe allergic reactions, including anaphylaxis
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on Anaphylm for severe allergic reactions, including anaphylaxis is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“the FDA has set a PDUFA action date of March 27, 2026”